Adjuvant chemotherapy in older women (ACTION) study – what did we learn from the pilot phase?
Robert Leonard(National Cancer Centre Japan), Judith M. Bliss(Institute of Cancer Research), Alistair Ring(National Health Service), J Mansi(St Thomas' Hospital), Andreas Makris(Institute of Cancer Research), L. Johnson(Michigan State University), Peter Ellis(Oldham Council), Lucy Kilburn(Institute of Cancer Research), Malcolm Reed(Yorkshire Cancer Research), Peter Simmonds(University of Turku), Rachel Ballinger(Brighton and Sussex Medical School), Lesley Fallowfield(Brighton and Sussex Medical School), Margot Gosney(Royal Berkshire NHS Foundation Trust), Gerry Thomas(Imperial College London), A. Robinson(Southend Hospital), David Cameron(Corewell Health)
Cited by 50
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k